THE USE OF PSYCHOTROPIC MEDICATIONS IN PWS

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. HYPOTHESIS Persons with Prader-Willi syndrome, aged 8 through adulthood, will not differ in their response to various types of psychotropic medications based on their genetic status or polymorphic differences of CYP450 enzyme activity from the population in general. SPECIFIC AIMS In this Pilot Project we specifically propose to: * Identify which regimes of psychotropic medications persons with PWS and their caregivers have found helpful, ineffective or harmful; * Relate treatment responsiveness in persons with PWS to their CYP450 enzyme status (CYP1A2, CYP2C19, CYP2D6, and CYP3A) specifically as rapid, poor, extensive and ultra rapid metabolizers; * Assess the clinical lore that persons with PWS are apt to respond to lower then expected or usual doses of medication due to be poor metabolizers; * Assess additional factors that might be associated with treatment response, including age, gender, genetic subtype of PWS, residential status, and current symptoms and maladaptive behaviors; * Disseminate such findings for both professionals and researchers in the field (e.g., peer-reviewed journals, presentations) and for families and caregivers of offspring with PWS (feedback, booklet, presentations at PWS meetings).